Drug maker Lupin launches chronic angina treatment drug in the US
"Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to the market, he added. Shares of Lupin were trading 0.29 per cent up at Rs 769.95 apiece on BSE.
Drug maker Lupin Thursday announced exclusive launch of Ranolazine extended-release (ER) tablets, indicated for the treatment of chronic angina, in the US market. The newly launched product, in strengths of 500 mg and 1,000 mg, is a generic version of Gilead Sciences' Ranexa ER tablets, Lupin said in BSE filing.
Quoting IQVIA MAT December 2018 data, Lupin said Ranolazine ER tablets, 500 mg and 1,000 mg had an annual sales of approximately USD 945 million in the US. "This is a meaningful product and further strengthens our portfolio of generic products in the US. Launching exclusive and semi-exclusive generics is an important stepping stone as we transition to more complex generics," Lupin Managing Director Nilesh Gupta said.
Watch This Zee Business Video
"Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to the market, he added. Shares of Lupin were trading 0.29 per cent up at Rs 769.95 apiece on BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
PM Modi has invested in this post office scheme; know his total worth as per Lok Sabha elections 2024 affidavit
SRH vs GT IPL 2024 Ticket Booking Online: Where and how to buy SRH vs GT tickets online - Check IPL Match 66 ticket price, other details
Top 7 SWP Mutual Funds: Rs 50 lakh investment, Rs 70K monthly pension for 10 years, and Rs 42.30 lakh balance value; know more details
Gold and Silver rate today (May 13, 2024): Precious metal under pressure; yellow metal near Rs 72,400, white metal above Rs 84,600
SIP Returns: How Rs 3,000, 5,000, and Rs 10,000 SIPs can help you build retirement corpus of Rs 1.06 cr, Rs 1.77 cr, and Rs 3.53 cr
TBO Tek IPO Listing LIVE Update: Bumper Debut! Share list at 55% premium - Buy, sell or hold? Check Anil Singhvi's view
02:00 PM IST